An interventional study of mobile venous thromboembolism application (mVTEA) in Venous Thromboembolism, Pulmonary Thromboembolisms and Digital Health, sponsored by Navy General Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Navy General Hospital, Beijing · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Venous Thromboembolism with a site in China — 21 open to participants now, 23 under way, 2 of them phase 3. Venous Thromboembolism · China.
Among the 62 studies in Venous Thromboembolism with a site in China, this one is the 7th largest by planned enrollment of the 33 interventional ones that give a count, is one of 5 that started in 2026, is one of 10 with no phase, reaches primary completion later than 20 of the 22 other live ones, and was the 48th registered.
714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.
Browse Venous Thromboembolism studies →21 of the 62 studies in Venous Thromboembolism with a site in China are open now. Recruiting first, the newest first:
Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
China-Japan Friendship Hospital · Sites in China
Ages 14+
The First Hospital of Jilin University · Sites in China
Ages 18+
Chen Lijuan · Sites in China
Ages 18–70
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,972 is above the median of 241 across 402 interventional studies indexed under Venous Thromboembolism.
Median enrollment 530 across the 33 interventional studies, 1,174 across the 29 observational. Of the 31 that completed or were terminated, 5 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 62 have an industry lead sponsor. The 10 most frequent:
Navy General Hospital, Beijing is the lead sponsor of 36 studies on the registry; 22 are open to participants now.
Navy General Hospital, Beijing has 4 studies filed under Venous Thromboembolism — fewer than ten, so there is no comparison to draw.
6 of the studies in Venous Thromboembolism with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06580223Phase 3Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma | 2027-09-01 |
| NCT02832245Manuel MonrealComputerized Registry of Patients With Venous Thromboembolism (RIETE) | 2026-12 |
| NCT07907211Chen LijuanAspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma | 2026-12-31 |
| NCT06950697Beijing Chao Yang HospitalDevelopment and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors | 2026-12-31 |
| NCT05378308Henan Provincial People's HospitalNOACs Use in AF or VTE (SUNSHINE Registry) | 2027-05-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 62 studies in Venous Thromboembolism with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.
This study aims to evaluate the effects of a smart technology-assisted, patient-centered mobile health application for pulmonary thromboembolism management (mPEA) on the long-term outcomes of patients with pulmonary thromboembolism (PTE). The findings are expected to inform clinical practice and provide an evidence base for the long-term management of patients with PTE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomly assigned to the mPEA management group will be discharged with mPEA-assisted patient-centered PTE management.
Other: mobile venous thromboembolism application (mVTEA)
Patients randomly assigned to the routine management group will be given routine post-discharge management in accordance with local clinical practice.
mVTEA will assist in the management of patients during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends venous thromboembolism (VTE)-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, voice, and video communication.
VTE-related composite event
The primary outcome was the occurrence of VTE-related composite event at 1-year follow-up, which was defined as a composite of recurrent VTE, newly diagnosed deep vein thrombosis (DVT), chronic thromboembolic pulmonary hypertension (CTEPH), major bleeding, VTE-related rehospitalization, and all-cause death.
Time frame: At 1-year follow-up
VTE events
VTE events will be documented at the 3, 6, 12, and 24-month follow-up after discharge. VTE events are categorized into two groups: recurrent VTE and newly diagnosed DVT. Recurrent VTE is defined as the appearance of new evidence of VTE after acute VTE has been treated in the acute phase (2 weeks) with significant clinical improvement in signs and symptoms. According to the time of VTE recurrence, it is further categorized into early VTE recurrence (within 3 months after the last VTE occurrence) and late VTE recurrence (more than 3 months after the last VTE occurrence). DVT that occurred for the first time after discharge during the study period is classified as newly diagnosed DVT.
Time frame: At 3, 6, 12, and 24-month follow-up
Chronic thromboembolic pulmonary hypertension (CTEPH)
The diagnosis of CTEPH will be documented at the 3, 6, 12, and 24-month follow-up.
Time frame: At 3, 6, 12, and 24-month follow-up
Chronic thromboembolic pulmonary disease (CTEPD)
The diagnosis of CTEPD will be documented at the 3, 6, 12, and 24-month follow-up after discharge.
Time frame: At 3, 6, 12, and 24-month follow-up
Post-pulmonary embolism syndrome (PPES)
The diagnosis of PPES will be documented at the 3, 6, 12, and 24-month follow-up after discharge
Time frame: At 3, 6, 12, and 24-month follow-up
Major bleeding
The major bleeding events as defined by the International Society on Thrombosis and Hemostasis (ISTH) will be documented at the 3, 6, 12, and 24-month follow-up after discharge.
Time frame: At 3, 6, 12, and 24-month follow-up
VTE-related hospitalization
Rehospitalization due to VTE recurrence, progression, or complications related to VTE treatment will be documented during the follow-up.
Time frame: At 3, 6, 12, and 24-month follow-up
Death
Death will be documented during the follow-up. It is categorized into all-cause death and PTE-related death. All-cause death is defined as death that occurs during the study period, regardless of cause. PTE-related death is defined as death that is unequivocally due to PTE.
Time frame: At 3, 6, 12, and 24-month follow-up
Patient-Reported Outcome Events (PROs)
PROs will be documented during the 3, 6, 12, and 24-month follow-up after discharge. PROs refer to information directly conveyed by patients themselves concerning their health status, symptoms, functional capacity, or adverse events related to treatment, without the need for interpretation or mediation by clinicians or other third parties.
Time frame: At 3, 6, 12, and 24-month follow-up
Generic quality of life
Generic, non-disease-specific health-related quality of life (QoL) is assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire and its corresponding visual analogue scale at 6, 12, and 24 months after discharge. Briefly, the EQ-5D-5L generates an overall index that ranges from 0 (lowest generic QoL) to 1 (highest generic QoL) and is calculated based on country-specific reference value sets. The EQ-5D-5L health index was calculated with the value set for China. The EuroQol visual analogue scale ranges from 0 to 100, with higher scores indicating better health.
Time frame: At 6, 12, and 24-month follow-up
Costs of management for healthcare staff
Costs of healthcare staff training (training duration × hourly wage), including training on standardized management of pulmonary embolism and the use of mVTEA; costs associated with post-discharge patient management by healthcare personnel (such as follow-up management, rehabilitation management, health counseling, and comorbidity management), calculated as (consultation time/re-hospitalization time × hourly wage); and development costs for mobile technology and intelligent algorithms.
Time frame: At 3, 6, and 12-month follow-up
Treatment costs for VTE-related patients
Treatment costs for VTE-related patients within 12 months post-discharge: These include registration fees, diagnostic costs, and treatment expenses incurred during visits to community clinics, hospital emergency departments, or specialist outpatient clinics due to changes in PTE condition (such as VTE recurrence, newly diagnosed DVT, bleeding, CTEPH, CTEPD, or PPES). They also encompass diagnostic and treatment expenses during hospital admissions in community or specialist settings due to changes in PTE condition. Additionally, costs arising from routine VTE follow-ups (without any changes in VTE-related conditions) at community clinics, hospital emergency departments, or specialist outpatient clinics are included.
Time frame: At 1-year follow-up
Treatment costs for non-VTE-related patients
Treatment costs for non-VTE-related patients within 12 months post-discharge: These comprise registration fees, diagnostic costs, and treatment expenses associated with visits to community clinics, hospital emergency departments, or specialist outpatient clinics for non-VTE-related conditions, as well as diagnostic and treatment expenses during hospital admissions in community or specialist settings for non-VTE-related diseases.
Time frame: At 3, 6, and 12-month follow-up
Anticoagulant adherence
Adherence would be assessed at months 3, 6, and 12 after discharge (defined as: the number of patients taking anticoagulants as prescribed/total number of patients at follow-up time point × 100%).
Time frame: At 3, 6, and 12-month follow-up
Probability of PTE progression
Clinical cure rate of PTE (defined as the numbers of patients without VTE recurrence, newly diagnosed DVT, bleeding, CTEPH, CTEPD, PPES, or all-cause mortality / total number of patients at the follow-up time point × 100% ); VTE (PTE/DVT) recurrence rate; incidence rate of newly diagnosed DVT; bleeding incidence rate; major bleeding incidence rate; non-major bleeding incidence rate; CTEPH incidence rate; CTEPD incidence rate; PPES incidence rate; all-cause mortality rate; PTE-related mortality rate would be collected.
Time frame: At 3, 6, and 12-month follow-up
Effectiveness evaluation
Quality-Adjusted Life Year(QALY) with EQ-5D-5L questionnaire would be investigated at 3, 6, and 12 months post-discharge and when the occurrence of VTE-related adverse events, including newly diagnosed DVT, bleeding, CTEPH, CTEPD, PPES, or all-cause mortality.
Time frame: At 3, 6, and 12-month follow-up
Plan to share: No
Started Aug 2026 (actual). Primary completion is estimated for Sep 2028, 25 months after the start.
Of 65 non-industry interventional studies with no phase under Venous Thromboembolism, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's planned 25 months is below that.
Counting every sponsor, half of 70 studies reached it within 31 months; a quarter within 19 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Navy General Hospital, Beijing